BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-117@catalystbrief.girapphe.com
DTSTAMP:20261117T181553Z
LAST-MODIFIED:20261117T181553Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: Jiangsu HengRui Medicine Co.\, Ltd. — Fuzuloparib \, Abi
 raterone acetate and Prednisone [Dec 2026]
DESCRIPTION:Phase 3 primary completion: A Multicenter\, Randomized\, Double
 -Blind\, Placebo-Controlled Phase III Study of Fuzuloparib Combined With A
 biraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P
  as First-Line Treatment in Patients With Metastatic Castration-Resistant 
 Prostate Cancer.\nSource: https://clinicaltrials.gov/study/NCT04691804\nht
 tps://catalystbrief.girapphe.com/e/117?lang=en\nNot investment advice. Dat
 es may change.
URL:https://catalystbrief.girapphe.com/e/117?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
